The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data

Research output: Contribution to journalArticle

Abstract

Crown Princess Margareta's Foundation, the Herman Järnhardt Foundation, the Foundation for Visually Impaired in Former Malmöhus County, Ögonfonden, Ingrid Nordmark's Foundation, the Margit and Kjell Stolz Foundation, foundations and donations administered by Skåne University Hospital, and King Gustav V and Queen Victoria's Freemason Foundation, Swedish Society for Medical Research, Swedish Medical Society Foundation and Cronqvist Foundation. Financial support was also provided through a regional agreement between Lund University and Skåne County Council (ALF) and by Umeå University and Västerbotten County Council (ALF).The sponsors and funding organizations had no role in the design or performance of this research.Acknowledgement/disclosures: The design of the GITS was briefly presented at the Nordic Glaucoma Congress in September 2017.The trial is supported by grants from Crown Princess Margareta's Foundation, the Herman Järnhardt Foundation, the Foundation for Visually Impaired in Former Malmöhus County, the Swedish Eye Foundation, Ingrid Nordmark's Foundation, the Margit and Kjell Stolz Foundation, foundations and donations administered by Skåne University Hospital, and King Gustav V and Queen Victoria's Freemason Foundation, Swedish Society for Medical Research, the Swedish Medical Society Foundation, and the Cronqvist Foundation. Financial support was also provided through a regional agreement between Lund University and Skåne County Council (ALF), and by Umeå University and Västerbotten County Council (ALF). The sponsors and funding organizations had no role in the design or performance of this research.Financial disclosures: Dr Bengtsson is a consultant to Carl Zeiss Meditec. Dr Heijl is a consultant to Carl Zeiss Meditec and Allergan, and has received speaking honoraria from Allergan, Zeiss and Santen. Dr Johannesson reports speaking honoraria and/or consulting for Topcon, Thea, Santen, Allergan, Alcon/Novartis. Dr Aspberg has received speaking honoraria from Allergan. Dr Andersson‐Geimer has nothing to disclose. Dr Lindén reports speaking honoraria from Allergan Nordic AB and Santen Pharma.

The trial is registered in EudraCT (Ref no. 2013‐002895‐42).

Details

Authors
Organisations
External organisations
  • Skåne University Hospital
  • Umeå University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Ophthalmology
Original languageEnglish
Pages (from-to)557-566
JournalActa Ophthalmologica
Volume96
Issue number(6)
Publication statusPublished - 2018 Aug 31
Publication categoryResearch
Peer-reviewedYes